The NG2-glia is a potential target to maintain the integrity of neurovascular unit after acute ischemic stroke

Hu, Xiaoyan; Geng, Panpan; Zhao, Xiaoyun; Wang, Qian; Liu, Changqing; Guo, Chun; Dong, Wen; Jin, Xinchun

doi:10.1016/j.nbd.2023.106076

Cited by 14 publications

(16 citation statements)

References 161 publications

(193 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, it was suggested that NG2 cells play a critical role in the modulation of neuroinflammation [ 131 ] and neurovascular unit formation during development [ 123 ] ( Figure 1 ). Although no TLRs have yet been identified in these cells, their importance in angiogenesis and oligodendrogenesis following acute ischemic stroke was reported [ 132 ]. Importantly, their ability to receive synapses from neurons and affect neuronal plasticity and behavior and their containment of nAChRs [ 133 , 134 ] suggest their potential use in specific therapeutic interventions.…”

Section: Synantocytes (Ng2 Cells)mentioning

confidence: 99%

“…Moreover, a critical role of NG2 cells in protecting the neurovascular unit and angiogenesis after acute ischemic stroke was recently suggested [ 123 ] ( Figure 3 ). It was proposed that exosomes derived from dental pulp stem cells may promote NG2-glia proliferation and differentiation and, hence, reduce tissue damage due to acute ischemic stroke [ 132 ]. Exosomes are small extracellular vesicles secreted by various stem cells and are potent mediators of intercellular communication and tissue repair [ 166 , 247 ].…”

Section: Nachrs–ng2 Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson’s Disease

Soares,

Costa,

Ferrolho

et al. 2024

Cells

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by resting tremor, bradykinesia, rigidity, and postural instability that also includes non-motor symptoms such as mood dysregulation. Dopamine (DA) is the primary neurotransmitter involved in this disease, but cholinergic imbalance has also been implicated. Current intervention in PD is focused on replenishing central DA, which provides remarkable temporary symptomatic relief but does not address neuronal loss and the progression of the disease. It has been well established that neuronal nicotinic cholinergic receptors (nAChRs) can regulate DA release and that nicotine itself may have neuroprotective effects. Recent studies identified nAChRs in nonneuronal cell types, including glial cells, where they may regulate inflammatory responses. Given the crucial role of neuroinflammation in dopaminergic degeneration and the involvement of microglia and astrocytes in this response, glial nAChRs may provide a novel therapeutic target in the prevention and/or treatment of PD. In this review, following a brief discussion of PD, we focus on the role of glial cells and, specifically, their nAChRs in PD pathology and/or treatment.

show abstract

Section: Synantocytes (Ng2 Cells)mentioning

confidence: 99%

Section: Nachrs–ng2 Cellsmentioning

confidence: 99%

Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson’s Disease

Soares,

Costa,

Ferrolho

et al. 2024

Cells

View full text Add to dashboard Cite

show abstract

“…More recently, it was suggested that NG2 cells play a critical role in modulation of neuroinflammation [131] and neurovascular unit formation during development [123] (Figure 1). Although yet no TLRs have yet been identified in these cells, their importance in angiogenesis and oligodendrogenesis following acute ischemic stroke has been reported [132]. Importantly, their ability to receive synapses from neurons and affect neuronal plasticity and behavior, and their containment of nAChRs [133,134] suggest their potential use in specific therapeutic interventions.…”

Section: Synantocytes (Ng2 Cells)mentioning

confidence: 99%

Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson’s Disease

Soares,

Costa,

Ferrolho

et al. 2024

Preprint

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by resting tremor, bradykinesia, rigidity, postural instability, that also includes non-motor symptoms such as mood dysregulation. Dopamine (DA) is the primary neurotransmitter involved in this disease, but cholinergic imbalance has also been implicated. Current intervention in PD is focused on replenishing central DA, which provides remarkable temporary symptomatic relief but does not address the neuronal loss and the progression of the disease. It has been well established that neuronal nicotinic cholinergic receptors (nAChRs) can regulate DA release and that nicotine itself may have neuroprotective effects. Recent studies have identified nAChRs in nonneuronal cell types including glial cells, where they may regulate inflammatory responses. Given the crucial role of neuroinflammation in dopaminergic degeneration, and the involvement of microglia and astrocytes in this response, glial nAChRs may provide a novel therapeutic target in prevention and/or treatment of PD. In this review, following a brief discussion of PD, we focus on the role of glial cells and specifically their nAChRs in PD pathology and/or treatment.

show abstract

“…BBB consists of brain microvascular endothelial cells, astrocytes endfeet, pericytes, basement membrane, and the extracellular matrix, and BBB is a highly specialized barrier 19 ( Fig. 1 A).…”

Section: Aging Neurological Diseases and Bbb Damagementioning

confidence: 99%

“…The BBB provides nutrients to the central nervous system (CNS), maintains homeostasis, and regulates its communication with the periphery, forming a protective barrier for the CNS 19 . The changes and destruction of the structure and functional components of the BBB could occur naturally with the aging process 20 .…”

Section: Introductionmentioning

confidence: 99%

Targeting the blood–brain barrier to delay aging-accompanied neurological diseases by modulating gut microbiota, circadian rhythms, and their interplays

The NG2-glia is a potential target to maintain the integrity of neurovascular unit after acute ischemic stroke

Cited by 14 publications

References 161 publications

Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson’s Disease

Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson’s Disease

Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson’s Disease

Targeting the blood–brain barrier to delay aging-accompanied neurological diseases by modulating gut microbiota, circadian rhythms, and their interplays

Contact Info

Product

Resources

About